AB
RXRX icon

Amalgamated Bank’s Recursion Pharmaceuticals RXRX Stock Holding History

Amalgamated Bank’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37K Hold
11,953
– – ﹤0.01% 1611
2025
Q4 		$49K Buy
11,953
+3,337
+39% +$16.5K ﹤0.01% 1846
2025
Q3 		$42K Hold
8,616
– – ﹤0.01% 1898
2025
Q2 		$44K Hold
8,616
– – ﹤0.01% 1853
2025
Q1 		$46K Buy
8,616
+1,464
+20% +$10.7K ﹤0.01% 1813
2024
Q4 		$48K Hold
7,152
– – ﹤0.01% 1842
2024
Q3 		$47K Hold
7,152
– – ﹤0.01% 1869
2024
Q2 		$54K Buy
7,152
+2,459
+52% +$21.4K ﹤0.01% 1840
2024
Q1 		$47K Sell
4,693
-7,251
-61% -$80.7K ﹤0.01% 1882
2023
Q4 		$118K Sell
11,944
-1,397
-10% -$9.96K ﹤0.01% 1949
2023
Q3 		$102K Hold
13,341
– – ﹤0.01% 1990
2023
Q2 		$100K Sell
13,341
-1,188
-8% -$8.31K ﹤0.01% 2063
2023
Q1 		$97K Sell
14,529
-3,294
-18% -$26.1K ﹤0.01% 2069
2022
Q4 		$137K Hold
17,823
– – ﹤0.01% 2004
2022
Q3 		$190K Buy
17,823
+306
+2% +$3.1K ﹤0.01% 1876
2022
Q2 		$143K Buy
17,517
+330
+2% +$2.21K ﹤0.01% 2025
2022
Q1 		$123K Sell
17,187
-1,347
-7% -$14.3K ﹤0.01% 2124
2021
Q4 		$317K Buy
+18,534
New +$349K ﹤0.01% 1793

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Amalgamated Bank's RXRX Position: Q1 2026 in Review

Amalgamated Bank held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 11,953 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #1611.

Amalgamated Bank first reported a position in RXRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $317K in Q4 2021. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Amalgamated Bank held 11,953 shares of Recursion Pharmaceuticals worth $37K as of Q1 2026.
  • Amalgamated Bank left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Amalgamated Bank's portfolio in Q1 2026, its #1611 holding.
  • Amalgamated Bank first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Amalgamated Bank's Recursion Pharmaceuticals position peaked at $317K in Q4 2021.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.